CERE Crosses Above Average Analyst Target
October 20, 2021 at 08:33 AM EDT
In recent trading, shares of Cerevel Therapeutics Holdings Inc (CERE) have crossed above the average analyst 12-month target price of $36.33, changing hands for $36.91/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..